22.10.2019BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Intevia™ 1mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system. The announcement was made at the Parental Drug Association’s 2019 Universe of Pre-Filled Syringes and Injection Devices conference being held in Gothenburg, Sweden. (...)

22.10.2019The new filter tester greatly improves the detectability of operator errors, improper test set-ups and out-of-tolerance environmental conditions. It is also more reliable and easier to use than ever before. With the Sartocheck® 5 Plus, false passed and false failed test results are therefore relegated to the past. Where other devices are limited in their flow measurement capability, this advanced filter tester has been designed to cover the complete range of integrity testing from small syringe filters up to large multi-round housings and crossflow cassettes, with diffusion rates of up to thousands of milliliters per minute. (...)
21.10.2019A three-day ‘Technology Open House” to celebrate innovation / Helping customers to be ‘future-ready’ / ACG Inspection, a division of ACG – the world’s only integrated pharmaceutical manufacturing and packaging solutions company - is to open a new ‘Centre of Excellence’ in Switzerland, supporting the company’s continued global expansion. The office will be the headquarters for logistics, development, data, service support, FAT and project management for ACG Inspections in Europe. To celebrate the launch in Yverdon, the company is holding a three-day ‘open doors’ celebration, inviting customers and media to join the team at the ‘Centre of Excellence’. At this event, ACG Inspection will showcase its future-ready technologies, such as: Brand Protection, Geo-Location Identification, Process Analytical Technology (PAT), Industrial Internet of Things (IIoT), Temperature Monitoring, Inspection 4.0 (AI Powered) (...)
21.10.2019Celltrion Healthcare today announced new data from a Phase 1 pivotal study to evaluate the pharmacokinetics (PK), efficacy and safety of CT-P13 SC compared to the CT-P13 IV formulation in people with inflammatory bowel disease (IBD). Results presented at UEG Week 2019 in Barcelona, Spain demonstrated non-inferiority of CT-P13 SC compared to CT-P13 IV in the PK primary endpoint at pre-dose level (Ctrough) at week 22, and in the secondary endpoints efficacy and safety up to week 30. / In the study, 136 patients were enrolled and 131 were randomised (66 to CT-P13 SC and 65 to CT-P13 IV). After loading doses of IV 5mg/kg at weeks 0 and 2, patients were randomised at week 6 to receive either CT-P13 SC 120mg (<80kg) or 240mg (≥80kg) every 2 weeks in the CT-P13 SC arm, or CT-P13 IV 5mg/kg every 8 weeks in the CT-P13 IV arm. (...)
21.10.2019Verfahren von Forschern der TU Wien hat Druckgeschwindigkeit von einem Meter pro Sekunde / Forscher der Technischen Universität Wien (TU Wien) http://tuwien.at haben ein neues Bioprinting-Verfahren entwickelt, mit dem sich lebende Zellen in feine Strukturen aus dem 3D-Drucker einbauen lassen - und das mit einer Druckgeschwindigkeit von einem Meter pro Sekunde. Das ist laut den Experten eine Größenordnung, die bisher nicht möglich war. (...)
21.10.2019UDI-Lasermarkierung als Gesamtpaket / Auf der Medica, einer der wichtigsten internationalen Medizintechnik-Messen (Messe Düsseldorf, 18. - 21. November 2019), ist FOBA mit seinen kamerabasierten Markierarbeitsplätzen der M-Serie vertreten, die sich für die UDI-Markierung besonders bewährt haben. FOBA bietet, basierend auf jahrzehntelanger Expertise mit Schwerpunkt Medizinindustrie, einen ganzheitlichen Markierprozess, der nicht nur innovative technische Lösungen, sondern auch die Validierung der Zeichen, die Qualifizierung von Prozess und Maschinen sowie Beratung und Service umfasst. (...)
21.10.2019Der bayerische Vorgründungs-Wettbewerb m4 Award unterstützt Gründungen für die Präzisionsmedizin – die Medizin der Zukunft / Der bayerische Vorgründungs-Wettbewerb m4 Award gibt aktuell die Gewinner bekannt. / Onkologie und Antibiotika-Resistenzen sind die Themen des diesjährigen m4 Award. / 2,5 Millionen Euro Förderung für innovative Projekte zur Entwicklung neuer Wirkstoffe gegen Erkrankungen mit einem hohen medizinischen Bedarf. (...)
21.10.2019Sartorius Stedim Biotech (SSB) (Paris:DIM) has agreed to acquire parts of Danaher’s Life Science portfolio as part of a broader transaction between Danaher and Sartorius Group, SSB’s major shareholder. The total purchase price is approximately $750 million in cash of which about a quarter will be allocated to the businesses purchased by SSB. The final purchase price allocation will be subject to the closing process. (...)
21.10.2019Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced the appointment of industry veteran Barbara S. Fox, Ph.D., to Chief Executive Officer. Dr. Fox succeeds interim Chief Executive Officer, Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will remain Chairman of Rheos Medicines’ board (...)
21.10.2019Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company’s clinical assets and cash resources, which amounted to $48.2 million as of June 30, 2019. (...)
Sie sehen Artikel 15761 bis 15770 von insgesamt 23175